MR Diagnosis of a Pulmonary Embolism: Comparison of P792 and Gd-DOTA for First-Pass Perfusion MRI and Contrast-Enhanced 3D MRA in a Rabbit Model
Korean Journal of Radiology
;
: 447-454, 2009.
Article
in English
| WPRIM
| ID: wpr-72779
ABSTRACT
OBJECTIVE:
To compare P792 (gadomelitol, a rapid clearance blood pool MR contrast agent) with gadolinium-tetraazacyclododecanetetraacetic acid (Gd-DOTA), a standard extracellular agent, for their suitability to diagnose a pulmonary embolism (PE) during a first-pass perfusion MRI and 3D contrast-enhanced (CE) MR angiography (MRA). MATERIALS ANDMETHODS:
A perfusion MRI or CE-MRA was performed in a rabbit PE model following the intravenous injection of a single dose of contrast agent. The time course of the pulmonary vascular and parenchymal enhancement was assessed by measuring the signal in the aorta, pulmonary artery, and lung parenchyma as a function of time to determine whether there is a significant difference between the techniques. CE-MRA studies were evaluated by their ability to depict the pulmonary vasculature and following defects between 3 seconds and 15 minutes after a triple dose intravenous injection of the contrast agents.RESULTS:
The P792 and Gd-DOTA were equivalent in their ability to demonstrate PE as perfusion defects on first pass imaging. The signal from P792 was significantly higher in vasculature than that from Gd-DOTA between the first and the tenth minutes after injection. The results suggest that a CE-MRA PE could be reliably diagnosed up to 15 minutes after injection.CONCLUSION:
P792 is superior to Gd-DOTA for the MR diagnosis of PE.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Organometallic Compounds
/
Pulmonary Embolism
/
Magnetic Resonance Imaging
/
Magnetic Resonance Angiography
/
Contrast Media
/
Imaging, Three-Dimensional
/
Heterocyclic Compounds
/
Injections, Intravenous
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Animals
Language:
English
Journal:
Korean Journal of Radiology
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS